Lands of 1995	ed	U.S. Patent ar	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 nd Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.
TRANSMITTAL FORM  (to be used for all correspondence after initial	Application Filing Date First Name	Number 09 09 07 od Inventor As	9/909,077 7/19/2001 shok Arasappan 653 avid Lukton N01156
Total Number of Pages in This Submission		Ocket Number	
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Change of Cor Terminal Discla Request for Re CD, Number of Remarks Also enclosed: (1) Marked-Up Arr (2) Response to Re (3) Sequence Listin (4) Sequence Listin	vert to a plication ney, Revocation respondence Address aimer fund f CD(s)  mendment - 2pgs. striction Requirement ag - 4pgs. ag on Floppy - 1 dis	Other Enclosure(s) (please Identify below): Certificate of Mailing (1pg.); Post Card; * Please see Remarks section  ent and Sequence Listing - 3pgs.  kette
Firm or Individual Palaiyur S. Kalyanaram Signature	an, Reg. No. 34,634	ANT, ATTORNEY	, OR AGENT
Date 07/31/2003	ERTIFICATE OF TE	SPTO or deposited with the	ho United States Deated Senior with aufficient

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Date

Typed or printed

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No.: IN01156 Application No.: 09/909,077

Filing Date: 07/19/2001 Inventor: Arasappan et al.

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



## Certificate of Mailing under 37 CFR 1.8

RECEIVED

AUG 0 7 2008

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

## **Commissioner for Patents**

P.O. Box 1450

Alexandria, VA 22313-1450 Mailstop: Non Fee Amendment

Date

Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents submitted:

Response Transmittal - 1pg.; Amendment - 3pgs

Marked-Up Amendment - 2pgs.

Response to Restriction Requirement and Sequence Listing - 3pgs.

Sequence Listing - 4pgs.

Sequence Listing on Floppy - 1 diskette; Post Card; Certificate of Mailing

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**PATENT: IN01156** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Arasappan *et al.*Serial No.: 09/909,077

PECEIVED

AUG 0 72003

TECH CENTER 1600/2000

Filed: July 19, 2001 ) Atty. Docket No.: IN01156

For: Novel Imidazolidinones as NS3-Serine Protease Inhibitors of Hepatitis C

Virus

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT AND SEQUENCE LISTING

Sir:

This communication is an Amendment and a response to the restriction requirement issued by the Examiner on July 15, 2003, in the above-identified patent application. Included in this communication are: a response to restriction requirement, an amendment to satisfy sequence listing, a sequence listing and a floppy disk containing said sequence listing.

Claims 1-47 are currently pending in the application. The Examiner restricted the claims into four groups (as subgenera) and twelve inventions: Group 1 (R1 limited to  $COR^5$ , and  $R^5$  is limited to  $N(R^9)(R^{10})$ ); Group 2 ( $R^1$  being moieties other than in Group 1); Group 3 (X limited to carbonyl or thiocarbonyl); and Group 4 (X limited to  $C[(R)(R')]_p$ ). The claims were divided up into 12 different ways to match the four groups.

Applicants are puzzled by these restrictions. Applicants believe that all claims 1-47 form part of one and the same invention. Applicants believe that when there is a linking claim (claim 1 here) encompassing the scope of all the processes, uses, composition and compounds, it is inappropriate to restrict the invention into these various inventions. Applicants also believe that due to such commonality, a complete examination of claims 1-47 as filed would not cause undue burden. Applicants further believe that the same art search will most probably apply to the alleged separate inventions, and respectfully submits that the restriction is improper.

Under the statute "two or more independent and distinct inventions.... in one application may.... be restricted to one of the inventions." Inventions are "independent" if "there is no disclosed relationship between two or more subjects disclosed" (MPEP 802.01). The term "distinct" means that "two or more subjects as disclosed are related.... but are capable of separate manufacture, use or sale as claimed, and are patentable over each other" (MPEP 802.01). However, even when patentably distinct inventions, restriction is not required unless one of the following reasons appear (MPEP 808.02):

- 1. Separate classification
- 2. Separate status in the art; or
- Different field of search.

In the present application, Applicants believe that the Examiner has not established a clear reason to establish the existence of any of the above 4 groups and 12 patentably distinct inventions. Reconsideration and withdrawal of the restriction requirement are, therefore, respectfully requested.

Furthermore, in order to comply with the Examiner's requirement, Applicants are electing, with traverse, the invention cited as Invention No. 3 by the Examiner as limited to groups 2 and 3. Applicants believe that this should also appropriately include the inventions classified as Invention Nos. 6, 7, 10 and 11 by the Examiner. Additionally, in order to comply with the requirement that a species be elected for examination purposes, Applicant is electing the following compound:

The above-shown compound occurs in Table 9 on page 67 of the application, as well as in Claim 43 (Compound No. 57).

Also enclosed herewith are an Amendment to satisfy the sequence listing, a Marked-up amendment and a sequence listing (paper copy and CRF on diskette).

If the Examiner has questions, the Examiner is invited to contact the undersigned.

Respectfully submitted,

Dr. Palaiyur S. Kalyanaraman Registration No. 34,634 Attorney for Applicants Tel: 908-298-5068

Fax: 908-298-5388